Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2018

DNMT3AR882-associated hypomethylation patterns are
maintained in primary AML xenografts, but not in the
DNMT3AR882C OCI-AML3 leukemia cell line
David Chen
Washington University School of Medicine in St. Louis

Matthew Christopher
Washington University School of Medicine in St. Louis

Nichole M. Helton
Washington University School of Medicine in St. Louis

Ian Freguson
Washington University School of Medicine in St. Louis

Timothy J. Ley
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Chen, David; Christopher, Matthew; Helton, Nichole M.; Freguson, Ian; Ley, Timothy J.; and Spencer, David
H., ,"DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but
not in the DNMT3AR882C OCI-AML3 leukemia cell line." Blood Cancer Journal. 8,4. 38. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7583

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
David Chen, Matthew Christopher, Nichole M. Helton, Ian Freguson, Timothy J. Ley, and David H. Spencer

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/7583

Chen et al. Blood Cancer Journal (2018)8:38
DOI 10.1038/s41408-018-0072-9

CORRESPONDENCE

Blood Cancer Journal

Open Access

DNMT3AR882-associated hypomethylation
patterns are maintained in primary AML
xenografts, but not in the DNMT3AR882C
OCI-AML3 leukemia cell line
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David Chen1, Matthew Christopher2, Nichole M. Helton2, Ian Ferguson2, Timothy J. Ley2,3 and David H. Spencer2,3

DNMT3AR882 mutations act as dominant negative
alleles in vitro1 and are associated with focal regions of
DNA hypomethylation in primary acute myeloid leukemia
(AML) samples and non-leukemic hematopoietic cells2.
In primary AML cells, this hypomethylation manifests
both as methylation loss and attenuated CpG island
hypermethylation relative to normal hematopoietic stem/
progenitor cells. Although DNMT3AR882 mutations have
a clear effect on DNA methylation in AML cells, the
functional consequences of these changes are not yet
clear. Future study of the downstream effects of mutant
DNMT3A-associated hypomethylation will require model
systems to investigate the genomic targets that are affected, and to understand whether these changes alter gene
regulation in ways that promote leukemogenesis. Examples of model systems include genetically modiﬁed mice,
patient-derived xenografts, and human cell lines containing DNMT3AR882 mutations. The methylation phenotypes of mice lacking Dnmt3a, or expressing mutant
Dnmt3a alleles, have been reported previously3–6, but
much less is known about whether alterations in methylation caused by DNMT3AR882 alleles are retained in
either patient-derived xenografts or human AML cell
lines, and whether these models could therefore be used
to accurately represent DNMT3AR882-dependent methylation changes in AML cells.
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To address this question, we performed whole-genome
bisulﬁte sequencing (WGBS) using DNA from OCIAML3 cells, which is the only leukemia cell line currently
known to have a native DNMT3AR882C mutation7. We
also evaluated four xenografts derived from a primary
AML sample containing the DNMT3AR882H mutation.
The OCI-AML3 line was obtained from the DSMZ cell
collection and cultured via recommended conditions
before DNA extraction at two independent passages for
WGBS. The presence of the DNMT3AR882C allele in these
cells was veriﬁed via targeted sequencing prior to
methylation analysis (Supplementary Figure S1), as were
the recurrent NPM1 exon 12 insertion (NPMc) and the
NRASQ61L mutation. No functional mutations were
identiﬁed in other recurrently mutated AML genes with
roles in epigenetic modiﬁcation, such as IDH1, IDH2,
ASXL1, EZH2, or TET2. Two missense variants of
unknown signiﬁcance were present in TET1 (Supplementary Table S2), which is not frequently mutated in
AML samples. Importantly, we saw no evidence for
ampliﬁcation of the wild-type DNMT3A allele in this cell
line (data not shown). We also extracted two replicate
DNA samples from comparator AML cell lines that are
wild-type for DNMT3A, including Kasumi-1 and NB4,
which have a t(8;21) translocation (creating the RUNX1RUNX1T1 fusion gene) and a t(15;17) translocation
(resulting in a PML-RARA fusion), respectively. Patientderived AML xenografts were generated in two independent humanized NSG mice (NSG-SGM3) from a
primary AML sample with the DNMT3AR882H mutation
(along with NPM1 and FLT3-ITD mutations; AML
721214, described as AML88 in ref. 8; Supplementary
Table S1) via tail vein injection of 1 million cells. Mice
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were killed at 16 weeks and ﬂow cytometry analysis of
bone marrow conﬁrmed high human AML cell engraftment (90% and 81% human CD45 chimerism in the
marrow, respectively; Supplementary Figure S2). Engrafted cells were subsequently transferred for two additional
passages in multiple mice, and DNA was isolated from
unmanipulated, xenografted bone marrow cells from both
primary and tertiary passages in duplicate. WGBS libraries
were prepared from all samples (including the primary
AML sample used for xenotransplantation) with 50ng of
DNA using the Swift DNA methylation library prep kit
and sequenced on Illumina HiSeq X instruments to obtain
277 million to 1.5 billion paired 150 bp reads per sample,
which yielded a median of 4 to 50-fold coverage for at
least 26 million CpGs in the human reference genome for
each sample (Supplementary Table S1).
We ﬁrst performed comparisons of genome-wide DNA
methylation levels between the AML cell lines, data from
normal human CD34+ cells, and primary AML samples
with and without DNMT3AR882 mutations2. The primary
AML samples demonstrated methylation patterns that
were previously reported to be associated with
DNMT3AR882 mutant AML samples, including lower
methylation overall, and at CpG island-shores, compared
to normal CD34 + cells. We also detected attenuated
hypermethylation at CpG islands compared to AMLs with
wild-type DNMT3A (Fig. 1a). In distinct contrast, CpGs in
all three AML cell lines were strikingly hypermethylated
at CpG islands and island-shores relative to the primary
human cell samples (34–51% mean methylation in the cell
lines at CpG islands, vs. 17–19% in the AML samples),
which is consistent with previous studies of methylation
in cancer cell lines compared to normal tissues9–11.
Interestingly, the mean methylation of OCI-AML3 and
NB4 cells across the entire genome was dramatically
lower than all other samples (68 and 64% for these two
cell lines, vs. 85% mean methylation for all other samples;
see Fig. 1a). This difference was manifest primarily as an
increase in large “partially-methylated domains” (PMDs;
Supplementary Figure S3), a phenomenon that has been
observed previously in some cell lines regardless of
DNMT3A mutation status, and that is associated with
transcriptionally inactive genomic regions12. The number
of PMDs was similar between the OCI-AML3 and NB4
cell lines (Figure S3A and S3B), indicating that these
features in OCI-AML3 cells cannot be uniquely attributed
to the DNMT3AR882 mutation. In contrast to all three cell
lines, methylation levels in the patient-derived xenografts
from AMLs with DNMT3AR882H closely resembled primary AML cells from the same tumor (and other AML
samples with DNMT3AR882H mutations) in all genomic
regions, including subtle hypomethylation at CpG islandshores, and attenuated hypermethylation of CpG islands
(Fig. 1a, blue points), as we described previously2.
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We next used results from our previously published
study of DNMT3A-dependent methylation in AML to
determine whether the 3,898 differentially methylated
regions (DMRs) that were hypomethylated in primary
AML cells with DNMT3AR882 were maintained in the
OCI-AML3 cells and patient xenografts. The OCIAML3 genome was not hypomethylated at these loci,
but in fact was hypermethylated relative to both AMLs
with DNMT3AR882 and normal CD34 cells (Fig. 1b).
Statistical analysis of these regions demonstrated that
81% (3,183/3,898) of the DMRs were hypermethylated in
OCI-AML3 cells compared to normal CD34 cells
(Supplementary Figure S4A), and 90% (3517/3898) were
hypermethylated
compared
to
the
primary
DNMT3AR882 AML samples (Supplementary Figure
S4B); a similar number of DMRs were hypermethylated
in Kasumi-1 and NB4 cells (85 and 82% vs. CD34 cells;
91 and 95% vs. DNMT3AR882 AML samples, respectively; Supplementary Figures S4C-F). We have shown
that hypomethylation in primary AML samples with
DNMT3AR882 reﬂects both methylation loss, and
reduced CpG island hypermethylation relative to normal
CD34 cells2; a review of individual DMR loci from both
of these categories demonstrates that OCI-AML3 cells
failed to recapitulate either of these phenotypes (Fig. 1c,
d). We performed the same analysis on the data from the
primary AML sample with the DNMT3AR882 mutation
that was used for xenotransplantation, and the two
passaged tumor cell populations from this sample: all
three were hypomethylated relative to the AML samples
that were wild-type for DNMT3A at most DMRs (e.g., >
73% of DMRs were statistically hypomethylated relative
to DNMT3AWT AML samples, Supplementary Figures
S4E-G). Xenotransplanted cells remained hypomethylated at these loci following two additional passages
through NSG-SGM3 mice (Supplementary Figure S5),
and the methylation relationships between samples with
DNMT3AR882 and normal CD34 cells were also preserved in all transplanted AML cells (Fig. 1c, d, and
Supplementary Figure S4).
Given the virtual absence of the focal, canonical hypomethylation phenotype in the OCI-AML3 cell line, we
performed additional experiments to assess the function
of DNMT3AR882 in this cell line. We veriﬁed that the
mutant and wild-type alleles of DNMT3A were expressed
equally in two replicate RNA-seq experiments (Supplementary Figure S6A). Overall expression levels of both
DNMT3A and DNMT3B (including active and inactive
isoforms) and other genes involved in DNA methylation
were also similar between OCI-AML3 cells and a previously published set of 32 primary AML samples2,
although expression of DNMT1 and BCAT113 were substantially higher in OCI-AML3 cells (Supplementary
Figure S6B). Surprisingly, the bulk in vitro methylation
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Fig. 1 DNMT3AR882-associated methylation patterns in primary AML cells, patient-derived xenografts, and AML cell lines. a Genome-wide
methylation statistics for all samples. Points show mean methylation values for all CpGs, CpG islands, and CpGs in island-shores for each sample. Note
that the primary AML samples with DNMT3AR882 mutations include four previously published samples2, and a ﬁfth sample that was used to generate
AML xenografts in four independent mice. b Methylation patterns at 3898 DNMT3A-dependent differentially methylated regions (DMRs) from
primary AML samples, AML cell lines, and xenografts. Each heatmap shows the mean methylation in 50 bp windows for a 6 kb window centered on a
DMR locus (one DMR per row), with methylation represented on a white (unmethylated) to red (methylated) scale. c, d Example DMRs with either
DNMT3AR882-associated hypomethylation (c), or loci with DNMT3A-mediated hypermethylation that is absent in AMLs with DNMT3AR882 (d). The top
tracks in each panel show mean methylation from normal CD34 cells (N = 5), AML samples with and without DNMT3AR882H/C (N = 4 each), and the
bottom tracks show the mean methylation from OCI-AML3, NB4, and Kasumi-1 cells (N = 2, each), and individual methylation levels for two AML
xenografts derived from AML sample 721214. All the methylation data in these panels were smoothed16 prior to plotting. Coordinates refer to human
reference sequence build 37 (hg19)

activity of OCI-AML3 cell lysates performed on an
unmethylated DNA substrate1 was signiﬁcantly higher
than Kasumi-1 cell lines (Figure S6C), even though
Kasumi-1 cells have signiﬁcantly higher CpG methylation
across the genome, suggesting that de novo methylation
in these cells is probably inﬂuenced by factors other than
DNMT3AR882.
Blood Cancer Journal

Models of DNMT3AR882 that accurately recapitulate the
epigenetic phenotype of primary AML samples with this
mutation will be critical to understand its functional
consequences, and investigate targeted therapies. In this
study, we found that DNMT3AR882-associated hypomethylation was preserved in patient-derived AML
xenografts with DNMT3AR882, which displayed the same
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global and focal hypomethylation phenotypes as primary
patient samples. The OCI-AML3 cell line, which harbors
a DNMT3AR882C allele, showed none of these patterns,
and were in fact hypermethylated at many of the
DNMT3A-dependent loci. Although these cells have been
used to represent AML samples with DNMT3AR882
mutations5,14,15, they are clearly not an appropriate model
for understanding DNMT3AR882-dependent methylation
phenotypes in AML cells, or for making inferences about
speciﬁc genes or loci that may be dysregulated by
DNMT3AR882. We have proposed that CpG island
hypermethylation may be a normal response to abnormal
proliferation in leukemic cells; these data suggest that the
residual de novo methylation activity present in OCIAML3 cells is adequate to methylate these DNMT3Adependent regions during long periods of cell culture. It is
also possible that these cells never possessed the
DNMT3AR882 methylation signature, although previous
analysis has shown that primary AML samples with
DNMT3AR882 invariably display some level of focal
hypomethylation at the loci examined here. Moreover, the
similarities between OCI-AML3 and other AML cells
lines with different initiating mutations suggests that the
methylation patterns in these cells may be related to
properties that are associated with immortalization.
Regardless, the methylation patterns in OCI-AML3, cells
are clearly very different from primary AML samples with
DNMT3AR882 mutations, and therefore this cell line is not
an appropriate model for understanding genomic patterns
of DNA methylation that are caused by the DNMT3AR882
mutation.
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